Shire Expands Rare Disease R&D With Boston Tie-Up
This article was originally published in The Pink Sheet Daily
Shire is teaming up with Children’s Hospital Boston to find therapies for rare pediatric diseases in a three-year collaboration that will capitalize on the strengths of both partners.
You may also be interested in...
Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov talked with “The Pink Sheet” about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.